References
- goldcopd.org [homepage on the Internet]Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); as current in 2017 Available from: http://goldcopd.orgAccessed March 26, 2017
- CelliBRThomasNEAndersonJAEffect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH studyAm J Respir Crit Care Med2008178433233818511702
- SpencerSCalverleyPMSherwood BurgePJonesPWISOLDE Study GroupInhaled Steroids in Obstructive Lung Disease. Health status deterioration in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001163112212811208636
- WilkeSJonesPWMullerovaHOne-year change in health status and subsequent outcomes in COPDThorax201570542042525782757
- DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
- AnzuetoAImpact of exacerbations on COPDEur Respir Rev20101911611311820956179
- SinghDMaleki-YazdiMRTombsLIqbalAFahyWANayaIPrevention of clinically important deteriorations in COPD with umeclidinium/vilanterolInt J Chron Obstruct Pulmon Dis2016111413142427445468
- BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
- WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
- WedzichaJABanerjiDChapmanKRIndacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPDN Engl J Med2016374232222223427181606
- ZhongNWangCZhouXLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
- VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
- goldcopd.org [homepage on the Internet]Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines; as current in 2008 Available from: http://goldcopd.orgAccessed March 26, 2017
- goldcopd.org [homepage on the Internet]Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); as current in 2009 Available from: http://goldcopd.orgAccessed March 26, 2017
- goldcopd.org [homepage on the Internet]Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); as current in 2010 Available from: http://goldcopd.orgAccessed March 26, 2017
- CelliBRCoteCGMarinJMThe body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary diseaseN Engl J Med2004350101005101214999112
- BriggsASpencerMWangHManninoDSinDDDevelopment and validation of a prognostic index for health outcomes in chronic obstructive pulmonary diseaseArch Intern Med20081681717918195198
- JonesRCDonaldsonGCChavannesNHDerivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE IndexAm J Respir Crit Care Med2009180121189119519797160
- CelliBRDecramerMLiuDMetzdorfNAsijeeGMTashkinDPDefining a COPD composite safety endpoint for demonstrating effi-cacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trialRespir Res20161714827141828
- NayaITombsTMullerovaHComptonCJonesPLong-term outcome following first clinically important deterioration in COPDEur Respir J201648304
- McMurrayJJPackerMDesaiASAngiotensin-neprilysin inhibition versus enalapril in heart failureN Engl J Med201437111993100425176015
- TsutsuiHMomomuraSSaitoYEfficacy and safety of sacu-bitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF studyJ Cardiol Epub20161223
- Maleki-YazdiMRSinghDAnzuetoATombsLFahyWANayaIAssessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three randomized trialsAdv Ther201733122188219927796912